Clinical Trial Update: A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study) [Phase 2]

View source ↗

Summary

Phase 2 ABRAZO study of talazoparib in locally advanced/metastatic breast cancer with BRCA mutations terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brca1-related Breast Cancer
• Brca2-related Breast Cancer
• Breast Cancer

Drugs mentioned

• Talazoparib (talazoparib)

Snippet

Sponsor: Pfizer | Conditions: Breast Neoplasms, BRCA 1 Gene Mutation | Phase 2 | Status: TERMINATED | Results posted: 2017-11-06